Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-673-6840
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable
Immunic (NASDAQ:IMUX) Frequently Asked Questions
What is Immunic's stock symbol?
Immunic trades on the NASDAQ under the ticker symbol "IMUX."
When is Immunic's next earnings date?
What price target have analysts set for IMUX?
1 Wall Street analysts have issued twelve-month price objectives for Immunic's shares. Their predictions range from $40.00 to $40.00. On average, they anticipate Immunic's stock price to reach $40.00 in the next year. This suggests a possible upside of 195.2% from the stock's current price. View Analyst Price Targets for Immunic.
What is the consensus analysts' recommendation for Immunic?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunic.
Has Immunic been receiving favorable news coverage?
Press coverage about IMUX stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Immunic earned a news impact score of 0.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Immunic.
Are investors shorting Immunic?
Immunic saw a increase in short interest during the month of June. As of June 30th, there was short interest totalling 140,700 shares, an increase of 8.1% from the May 30th total of 130,100 shares. Based on an average trading volume of 219,300 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.3% of the company's shares are sold short. View Immunic's Current Options Chain.
Who are some of Immunic's key competitors?
Some companies that are related to Immunic include IMMUTEP LTD/S (IMMP), Aquinox Pharmaceuticals (AQXP), Relmada Therapeutics (RLMD), Agile Therapeutics (AGRX), Adamis Pharmaceuticals (ADMP), PLx Pharma (PLXP), Medicure (MCUJF), Moleculin Biotech (MBRX), VERONA PHARMA P/S (VRNA), Eyenovia (EYEN), Elite Pharmaceuticals (ELTP), IVERIC bio (ISEE), Vascular Biogenics (VBLT), Ophthotech (OPHT) and Vaccinex (VCNX).
Who are Immunic's key executives?
Immunic's management team includes the folowing people:
- Dr. Daniel Vitt, CEO, Pres & Director (Age 51)
- Dr. Manfred Gröppel, Co-Founder & COO
- Dr. Andreas Mühler Ph.D., Co-Founder and Chief Medical Officer (Age 56)
- Ms. Tamara A. Seymour, Interim Chief Financial Officer (Age 60)
- Dr. Hella Kohlhof, Chief Scientific Officer
How do I buy shares of Immunic?
Shares of IMUX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immunic's stock price today?
One share of IMUX stock can currently be purchased for approximately $13.55.
How big of a company is Immunic?
Immunic has a market capitalization of $14.36 million. The company earns $-41,470,000.00 in net income (profit) each year or ($35.60) on an earnings per share basis. View Additional Information About Immunic.
What is Immunic's official website?
How can I contact Immunic?
Immunic's mailing address is 15222-B AVENUE OF SCIENCE, SAN DIEGO CA, 92128. The company can be reached via phone at 858-673-6840 or via email at [email protected]
MarketBeat Community Rating for Immunic (NASDAQ IMUX)
MarketBeat's community ratings are surveys of what our community members think about Immunic and other stocks. Vote "Outperform" if you believe IMUX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMUX will underperform the S&P 500 over the long term. You may vote once every thirty days.
